

# Frédéric Baron

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3805512/publications.pdf>

Version: 2024-02-01

191  
papers

9,416  
citations

57631

44  
h-index

43802

91  
g-index

194  
all docs

194  
docs citations

194  
times ranked

9100  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. <i>Blood</i> , 2005, 106, 2912-2919.	0.6	2,427
2	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 906-912.	1.3	364
3	Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2005, 23, 1993-2003.	0.8	312
4	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 972-979.	0.8	296
5	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2015, 50, 781-789.	1.3	294
6	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2004, 104, 2254-2262.	0.6	226
7	Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus-Host Disease (GVHD) without Abrogating Graft-versus-Tumor Effects after HLA-Mismatched Allogeneic Transplantation following Nonmyeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 838-847.	2.0	193
8	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. <i>Leukemia</i> , 2012, 26, 2462-2468.	3.3	170
9	Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2016, 51, 1431-1438.	1.3	161
10	Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Leukemia</i> , 2006, 20, 1690-1700.	3.3	160
11	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 2941-2951.	2.0	140
12	Monoclonal antibodies against GARP/TGF- $\beta$ 1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. <i>Science Translational Medicine</i> , 2015, 7, 284ra56.	5.8	130
13	Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase II, open-label, clinical study. <i>Journal of Hepatology</i> , 2017, 67, 47-55.	1.8	110
14	Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 224-234.	1.7	108
15	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 788-800.	1.3	106
16	Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2006, 24, 4150-4157.	0.8	104
17	Mesenchymal Stromal Cells: A New Tool against Graft-versus-Host Disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 822-840.	2.0	99
18	High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. <i>Leukemia</i> , 2005, 19, 822-828.	3.3	96

#	ARTICLE	IF	CITATIONS
19	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015, 126, 2062-2069.	0.6	93
20	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014, 49, 389-396.	1.3	92
21	Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. <i>Seminars in Immunopathology</i> , 2004, 26, 71-94.	4.0	84
22	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. <i>Annals of Hematology</i> , 2016, 95, 191-199.	0.8	84
23	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019, 184, 782-787.	1.2	82
24	Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2010, 45, 689-693.	1.3	78
25	Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. <i>Oncotarget</i> , 2016, 7, 37931-37943.	0.8	78
26	Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , 2015, 121, 1048-1055.	2.0	77
27	Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. <i>Kidney International</i> , 2019, 95, 693-707.	2.6	74
28	Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. <i>Haematologica</i> , 2011, 96, 298-306.	1.7	71
29	Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning. <i>Blood Reviews</i> , 2005, 19, 153-164.	2.8	70
30	Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 205-221.	1.9	66
31	Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. <i>Molecular Therapy</i> , 2006, 13, 26-41.	3.7	64
32	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 1810-1822.	1.7	64
33	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. <i>Bone Marrow Transplantation</i> , 2020, 55, 485-495.	1.3	61
34	Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. <i>Leukemia</i> , 2017, 31, 26-33.	3.3	59
35	Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice. <i>Frontiers in Immunology</i> , 2018, 9, 1943.	2.2	58
36	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 519-530.	1.3	54

#	ARTICLE	IF	CITATIONS
37	Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. <i>Oncolmmunology</i> , 2017, 6, e1314425.	2.1	53
38	What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 580-588.	2.0	52
39	Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. <i>Cytotherapy</i> , 2013, 15, 267-279.	0.3	51
40	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	1.7	51
41	Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. <i>Frontiers in Immunology</i> , 2019, 10, 619.	2.2	50
42	IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 200-209.e8.	1.5	49
43	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 272-279.	2.0	48
44	Hematopoietic cell transplantation: five decades of progress. <i>Archives of Medical Research</i> , 2003, 34, 528-544.	1.5	47
45	Unrelated Donor Status and High Donor Age Independently Affect Immunologic Recovery after Nonmyeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1176-1187.	2.0	46
46	Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease. <i>Transfusion</i> , 2014, 54, 353-363.	0.8	46
47	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1406-1414.	2.0	44
48	Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. <i>Current Opinion in Hematology</i> , 2007, 14, 145-151.	1.2	43
49	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 256-262.	1.7	42
50	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016, 7, 43027-43038.	0.8	40
51	Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. <i>PLoS ONE</i> , 2015, 10, e0130026.	1.1	40
52	Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Hematology and Oncology</i> , 2021, 14, 174.	6.9	40
53	Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2006, 81, 818-825.	0.5	38
54	Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. <i>Haematologica</i> , 2008, 93, 240-247.	1.7	38

#	ARTICLE	IF	CITATIONS
55	Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning. <i>Clinical Cancer Research</i> , 2015, 21, 3131-3139.	3.2	38
56	Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2Â Gy TBI or ATG plus 8Â Gy TLI: a phase II randomized study from the Belgian Hematological Society. <i>Journal of Hematology and Oncology</i> , 2015, 8, 4.	6.9	37
57	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 431-437.	1.3	37
58	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 532-535.	1.3	36
59	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. <i>Bone Marrow Transplantation</i> , 2022, 57, 215-223.	1.3	36
60	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood—a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 107.	6.9	35
61	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016, 101, 773-780.	1.7	35
62	Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. <i>Current Opinion in Hematology</i> , 2005, 12, 435-443.	1.2	34
63	Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. <i>Expert Review of Hematology</i> , 2016, 9, 297-314.	1.0	34
64	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , 2018, 2, 2127-2135.	2.5	34
65	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
66	Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. <i>Journal of Hematology and Oncology</i> , 2016, 9, 53.	6.9	33
67	Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2000, 110, 339-342.	1.2	32
68	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. <i>Clinical Cancer Research</i> , 2018, 24, 2794-2803.	3.2	32
69	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 218-224.	1.3	32
70	Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 351-359.	2.0	31
71	Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial. <i>American Journal of Hematology</i> , 2013, 88, 990-996.	2.0	29
72	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6478-6486.	3.2	28

#	ARTICLE	IF	CITATIONS
73	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. <i>PLoS ONE</i> , 2016, 11, e0150637.	1.1	28
74	The veno-occlusive disease of the liver. <i>Haematologica</i> , 1997, 82, 718-25.	1.7	27
75	Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial. <i>Blood</i> , 2014, 124, 33-41.	0.6	26
76	Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. <i>Journal of Internal Medicine</i> , 2018, 283, 178-189.	2.7	26
77	Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. <i>Experimental Hematology</i> , 2002, 30, 546-554.	0.2	25
78	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. <i>Transfusion</i> , 2000, 40, 468-476.	0.8	24
79	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Annals of Hematology</i> , 2019, 98, 2389-2398.	0.8	24
80	In Vitro Th17-Polarized Human CD4+ T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 204-215.	2.0	24
81	Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. <i>Transfusion and Apheresis Science</i> , 2011, 44, 205-210.	0.5	23
82	Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2015, 126, 863-863.	0.6	23
83	Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 957-972.	1.9	22
84	T-cell reconstitution after unmanipulated, CD8-depleted or CD34-selected nonmyeloablative peripheral blood stem-cell transplantation. <i>Transplantation</i> , 2003, 76, 1705-1713.	0.5	21
85	Intensified Postgrafting Immunosuppression Failed to Assure Long-Term Engraftment of Dog Leukocyte Antigen-Identical Canine Marrow Grafts After 1 Gray Total Body Irradiation. <i>Transplantation</i> , 2008, 85, 1023-1029.	0.5	21
86	The Prosurvival IKK-Related Kinase IKK $\mu$ Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine. <i>Cancer Research</i> , 2016, 76, 2587-2599.	0.4	21
87	Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. <i>Leukemia</i> , 2017, 31, 1408-1414.	3.3	21
88	Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 128.	6.9	21
89	Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. <i>Oncotarget</i> , 2015, 6, 43255-43266.	0.8	21
90	Myasthenia gravis without chronic GVHD after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1998, 22, 197-200.	1.3	20

#	ARTICLE	IF	CITATIONS
91	Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 163-174.	1.4	20
92	Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft-versus-Host Disease after Unrelated Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1041-1048.	2.0	19
93	Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin <i>versus</i> allogeneic bone marrow transplantation without anti-thymocyte globulin. <i>Haematologica</i> , 2020, 105, 1138-1146.	1.7	19
94	SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 30712-30729.	0.8	19
95	Nonmyeloablative Stem Cell Transplantation with CD8-Depleted or CD34-Selected Peripheral Blood Stem Cells. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 301-314.	1.8	18
96	Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT. <i>Blood Cancer Journal</i> , 2019, 9, 46.	2.8	18
97	Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2000, 111, 745-53.	1.2	18
98	Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 243-263.	1.8	17
99	Molecular mechanisms, current management and next generation therapy in myeloma bone disease. <i>Leukemia and Lymphoma</i> , 2018, 59, 14-28.	0.6	17
100	Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. <i>Cancer Cell</i> , 2022, , .	7.7	17
101	Donor lymphocyte infusion to eradicate recurrent host hematopoiesis after allogeneic BMT for sickle cell disease. <i>Transfusion</i> , 2000, 40, 1071-1073.	0.8	16
102	Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. <i>Bone Marrow Transplantation</i> , 2010, 45, 1442-1448.	1.3	16
103	Impact of Cotransplantation of Mesenchymal Stem Cells on Lung Function After Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Following Non-Myeloablative Conditioning. <i>Transplantation</i> , 2014, 98, 348-353.	0.5	16
104	Cellular immunotherapy in multiple myeloma: Lessons from preclinical models. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 392-404.	3.3	16
105	Itacitinib prevents xenogeneic GVHD in humanized mice. <i>Bone Marrow Transplantation</i> , 2021, 56, 2672-2681.	1.3	16
106	Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study. <i>Oncotarget</i> , 2018, 9, 20590-20604.	0.8	16
107	Spontaneous atopic dermatitis due to immune dysregulation in mice lacking Adamts2 and 14. <i>Matrix Biology</i> , 2018, 70, 140-157.	1.5	15
108	Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients. <i>Haematologica</i> , 2020, 105, e13-e16.	1.7	15

#	ARTICLE	IF	CITATIONS
109	Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature. <i>Acta Clinica Belgica</i> , 2021, 76, 500-508.	0.5	15
110	Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation. <i>Haematologica</i> , 1998, 83, 1076-81.	1.7	15
111	Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment. <i>Clinical Cancer Research</i> , 2003, 9, 5566-72.	3.2	15
112	Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease. <i>Haematologica</i> , 2018, 103, 1359-1368.	1.7	14
113	Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. <i>Transplantation</i> , 2002, 74, 1692-1696.	0.5	13
114	What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 335-344.	2.0	13
115	High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT. <i>Bone Marrow Transplantation</i> , 2015, 50, 341-347.	1.3	13
116	Growth Hormone (GH) Deficient Mice With GHRH Gene Ablation Are Severely Deficient in Vaccine and Immune Responses Against <i>Streptococcus pneumoniae</i> . <i>Frontiers in Immunology</i> , 2018, 9, 2175.	2.2	13
117	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
118	Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): a prospective study from the Belgian Hematology Society (BHS). <i>Bone Marrow Transplantation</i> , 2022, 57, 116-118.	1.3	13
119	Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. <i>Haematologica</i> , 2019, 104, 1168-1175.	1.7	12
120	Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 188, 428-437.	1.2	12
121	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2020, 95, 1057-1065.	2.0	12
122	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. <i>American Journal of Hematology</i> , 2020, 95, 749-758.	2.0	12
123	Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion. <i>British Journal of Haematology</i> , 2003, 123, 103-105.	1.2	11
124	Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. <i>American Journal of Transplantation</i> , 2021, 21, 2662-2674.	2.6	11
125	Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2014, 9, e113764.	1.1	11
126	Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood stem cell transplantation when started soon after engraftment. <i>Haematologica</i> , 2003, 88, 718-20.	1.7	11



#	ARTICLE	IF	CITATIONS
127	Long-term safety follow-up of a randomized trial of darbepoetin alpha and intravenous iron following autologous hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2015, 90, E133-4.	2.0	10
128	Failure of Donor Lymphocyte Infusion to Prevent Graft Rejection in Dogs Given DLA-Identical Marrow after 1 Gy of Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 813-817.	2.0	9
129	Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 173-192.	1.0	9
130	Kinetics of IL-7 and IL-15 Levels after Allogeneic Peripheral Blood Stem Cell Transplantation following Nonmyeloablative Conditioning. <i>PLoS ONE</i> , 2013, 8, e55876.	1.1	9
131	Sputum cytokine levels in patients undergoing hematopoietic SCT and comparison with healthy subjects and COPD: a pilot study. <i>Bone Marrow Transplantation</i> , 2014, 49, 1382-1388.	1.3	9
132	Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers. <i>Talanta</i> , 2014, 125, 265-275.	2.9	9
133	Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: Low donor chimerism predicts for poor response. <i>Experimental Hematology</i> , 2006, 34, 841-850.	0.2	8
134	Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial. <i>Leukemia</i> , 2009, 23, 608-610.	3.3	8
135	Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission – a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 184, 643-646.	1.2	8
136	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 917-927.	1.3	8
137	373: What is the Role for Regulatory T-cells after Nonmyeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 136-137.	2.0	7
138	Erythropoietin therapy after allogeneic hematopoietic cell transplantation has no impact on long-term survival. <i>American Journal of Hematology</i> , 2015, 90, E197-9.	2.0	7
139	Serum hepcidin following autologous hematopoietic cell transplantation: an illustration of the interplay of iron status, erythropoiesis and inflammation. <i>Haematologica</i> , 2014, 99, e35-e37.	1.7	6
140	Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?. <i>Bone Marrow Transplantation</i> , 2016, 51, 640-642.	1.3	6
141	Cytotoxic T-lymphocyte-associated protein 4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1394-1403.e8.	1.5	6
142	Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials. <i>Cancers</i> , 2020, 12, 3334.	1.7	6
143	Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1964-1970.	1.3	6
144	Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. <i>Haematologica</i> , 2002, 87, 78-88.	1.7	6

#	ARTICLE	IF	CITATIONS
145	Thinking Out of the Box—New Approaches to Controlling GVHD. Current Hematologic Malignancy Reports, 2014, 9, 73-84.	1.2	5
146	Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica, 2017, 102, e47-e51.	1.7	5
147	Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Cancers, 2021, 13, 3072.	1.7	5
148	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 2742-2748.	1.3	5
149	Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based Model Using The Data Set of The Acute Leukemia Working Party (ALWP) Of The EBMT. Blood, 2013, 122, 409-409.	0.6	5
150	Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. Frontiers in Immunology, 2022, 13, 827242.	2.2	5
151	Human leukocyte antigen haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients 55 years of age. American Journal of Hematology, 2022, 97, 1065-1074.	2.0	5
152	Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. British Journal of Haematology, 2000, 111, 745-753.	1.2	4
153	Transfusions after nonmyeloablative or reduced-intensity conditioning regimens. Leukemia, 2006, 20, 2081-2086.	3.3	4
154	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. Annals of Hematology, 2018, 97, 1785-1795.	0.8	4
155	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. Journal of Internal Medicine, 2019, 285, 446-454.	2.7	4
156	How to Make an Immune System and a Foreign Host Quickly Cohabit in Peace? The Challenge of Acute Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 583564.	2.2	4
157	Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant. American Journal of Hematology, 2021, 96, 1275-1286.	2.0	4
158	Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials. Blood, 2013, 122, 829-829.	0.6	4
159	Retrospective Comparison of CD34-selected Allogeneic Peripheral Blood Stem Cell Transplantation Followed by CD8-depleted Donor Lymphocyte Infusions with Unmanipulated Bone Marrow Transplantation. Hematology, 2002, 7, 137-143.	0.7	3
160	Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC. Bone Marrow Transplantation, 2003, 32, 829-834.	1.3	3
161	Boosting regulatory T cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT061). Immunology and Cell Biology, 2015, 93, 321-322.	1.0	3
162	High proportion of terminally differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 1828-1841.	1.3	3

#	ARTICLE	IF	CITATIONS
163	Regulatory T cells fulfil their promise?. Immunology and Cell Biology, 2011, 89, 825-826.	1.0	2
164	Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 461-469.	1.3	2
165	Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study. Blood, 2019, 134, 37-37.	0.6	2
166	Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 2016, 11, e0167997.	1.1	2
167	Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report. Frontiers in Immunology, 2022, 13, 889148.	2.2	2
168	Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, S393.	2.0	1
169	Unrelated donor haemopoietic stem-cell transplantation: ATG or not?. Lancet Haematology,the, 2017, 4, e252-e253.	2.2	1
170	Busulfan or melphalan: is there a better conditioning regimen for allogeneic transplantation?. Leukemia and Lymphoma, 2020, 61, 1529-1534.	0.6	1
171	Treatment of a patient with severe cytomegalovirus (CMV) infection after haploidentical stem cell transplantation with donor-derived CMV-specific T cells. Acta Clinica Belgica, 2020, 76, 1-5.	0.5	1
172	Stem Cell Therapy: Past, Present, and Future. , 2008, , 561-591.		1
173	Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.. Blood, 2005, 106, 1143-1143.	0.6	1
174	Donor NK Cell Engraftment and Overall and Progression-Free Survivals after Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.. Blood, 2005, 106, 398-398.	0.6	1
175	Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prophylaxis in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in First Complete Remission: A Survey on Behalf of the EBMT Acute Leukemia Working Party. Blood, 2016, 128, 4563-4563.	0.6	1
176	Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML. Haematologica, 2002, 87, ECR43.	1.7	1
177	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 0, ...	1.3	1
178	Immune recovery predicts survival after T-cell depleted allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2017, 58, 1774-1776.	0.6	0
179	Graft-versus-host disease does not help acute lymphoblastic leukaemia patients with measurable residual disease. British Journal of Haematology, 2020, 190, 22-23.	1.2	0
180	Graft-versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning.. Blood, 2004, 104, 184-184.	0.6	0

#	ARTICLE	IF	CITATIONS
181	HLA-Matched Unrelated Donor HCT after Nonmyeloablative Conditioning for Patients with Chronic Myeloid Leukemia.. Blood, 2004, 104, 2755-2755.	0.6	0
182	Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study. Blood, 2017, 130, 907-907.	0.6	0
183	Outcomes of Graft Failures after Umbilical Cord Blood Transplantation in Acute Leukemia: A Study from Eurocord and the Acute Leukemia Working Party of the EBMT. Blood, 2017, 130, 661-661.	0.6	0
184	Profiling T Cell Receptor Repertoires in Phase I/II Clinical Trials of Donor Treg Infusion for the Treatment of Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 4563-4563.	0.6	0
185	Underdiagnosed Venous-occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party. Blood, 2019, 134, 4483-4483.	0.6	0
186	The Disease-Risk Stratification Scheme (DRSS), a Contemporary Risk-Stratification System for Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 43-43.	0.6	0
187	Oral Minocycline As Systemic Therapy for Uncomplicated Venous Access Device-Related Bloodstream Infection with Coagulase-Negative Staphylococci in Patients after Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 4859-4859.	0.6	0
188	Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2021, 138, 3964-3964.	0.6	0
189	Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee. Blood, 2020, 136, 27-29.	0.6	0
190	Individualised doses of anti-thymocyte globulin and immune recovery after allogeneic HSCT. Lancet Haematology, the, 2022, 9, e84-e86.	2.2	0
191	Serological response to SARS-CoV-2 mRNA-containing lipid nanoparticle vaccine in patients with multiple myeloma: A negative impact of CD38 <sup>+</sup> regulatory T cells?. British Journal of Haematology, 2022, , .	1.2	0